NEW YORK, April 11 - Genmab and Paradigm Therapeutics today said they plan to co-develop new antibody therapeutics.

The partners will combine Paradigm's disease targets and bioinformatics platform with Genmab's fully human antibody technology to develop therapeutics for cancer, inflammatory diseases, and other states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.